UNSPSC 51392223: Indanazoline hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H15N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z364A90IV8, chemically known as 2-imidazoline, 2-(4-indanylamino)-, hydrochloride but more generally known as indanazoline hydrochloride, which bears US NIH Compound Identifier 162014. European Medicines Agency schedules Indanazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02661MIG.

Most nations, for tariff and trade purposes, schedule indanazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, INDANAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Indanazoline hydrochloride bears US NLM identifiers UMLS ID C1609361 and NCI Concept Code C97700. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCC2.CL.

UNSPSC 51392223 Indanazoline hydrochloride is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health authorities. The recent opportunities tagged to this code show a mismatch with the code's nominal scope: the Seminole County solicitation targets naloxone and drug deactivation systems (emergency overdose-response products), while the Texas HHS Commission RFI addresses direct-to-manufacturer prescription fulfillment programs. Neither opportunity directly involves indanazoline hydrochloride procurement. State and local governments do procure pharmaceutical products and active ingredients through this code tier, but the recent activity does not reflect the specific compound named in the code's definition.

The limited recent activity under this code suggests it sees infrequent solicitation at the state and local level. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for naloxone and safe drug deactivation systems with quarterly deliveries to the county's Community Health Building in Sanford, ordering 1,900 units of naloxone and 800 deactivation systems annually on a two-year contract with one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response deadline April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling state interest in alternative pharmaceutical procurement models. The code shows activity concentrated in Florida and Texas, though the divergence between the code's definition and the actual work being solicited suggests either a tagging error in the underlying opportunities or that indanazoline hydrochloride itself is rarely procured through state and local channels.